Don't Miss

May & Baker gets WHO certification

By on November 30, 2014

The World Health Organisation has certified May & Baker Nigeria Plc as a pharmaceutical manufacturing company with adequate facilities and processes that meet the global health organisation’s current Good Manufacturing Practice, a statement from the company said.

The development was the result of a deliberate and sustained effort by the company to seek international accreditation and certification for its production processes and products.

May & Baker, which expanded its operations with the construction of a manufacturing complex, the PharmaCentre, in Ota, Ogun State a few years back, said the certification had opened a vast opportunity for global drug manufacturing contracts to it.

The company explained that its journey towards the attainment of the cGMP certification started in 2008 when it began building the PharmaCentre.

It said the facility, which was inaugurated in 2011, was designed to meet all requirements of international pharmaceutical manufacturing best practice, from civil works to equipment installations, quality assurance, input supply and production processes.

It was in 2012, after the new plant had commenced operations that the company formally applied to the WHO for GMP certification. This was followed by the inspection of the plant by WHO experts on four times in two years.

The Managing Director, May & Baker, Mr. Nnamdi Okafor, was quoted as saying that the company had become synonymous with excellence since it started operations in Nigeria in 1944 as the first pharmaceutical company in the country.

According to him, the WHO certification is not an end in itself but a source of motivation for the company to pursue new goals “in the quest for excellent health care delivery in Nigeria.”

The company, which said the WHO certification confirmed that the funds committed in the Pharmacentre was justified, assured its shareholders that the certification would serve as a springboard for greater participation in the local and international pharmaceutical markets.

Okafor, however, pointed out that the WHO’s prequalification of products was not yet over as the company would soon commence the next stage, which would involve the presentation of specific products for prequalification by WHO.